Related Experiment Video

Updated: Jun 5, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Sobetirome: a selective thyromimetic for the treatment of dyslipidemia

Ivan Tancevski1, Egon Demetz, Philipp Eller

  • 1Department of Internal Medicine, Innsbruck Medical University, Innsbruck, Austria. ivan.tancevski@i-med.ac.at

Recent Patents on Cardiovascular Drug Discovery
|January 7, 2011
PubMed

Insights

Thyroid hormone receptor-selective analogs, like sobetirome (GC-1), offer a new way to treat dyslipidemia. These drugs lower cholesterol and triglycerides by enhancing liver LDL receptor activity and promoting cholesterol removal.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Cardiovascular Medicine

Background:

  • Atherosclerosis is a leading cause of death globally.
  • Dyslipidemia is a major risk factor for coronary artery disease.
  • Liver and thyroid hormone receptor β-selective analogs represent a novel drug class for dyslipidemia.

Purpose of the Study:

  • To review recent patents for sobetirome (GC-1).
  • To discuss sobetirome's mechanisms for lowering plasma lipids.
  • To highlight the potential of thyromimetics in managing cardiovascular risk.

Main Methods:

  • Review of recent patents concerning sobetirome (GC-1).
  • Analysis of the pharmacological mechanisms of sobetirome's lipid-lowering effects.
  • Focus on hepatic LDL receptor induction, reverse cholesterol transport, and bile acid secretion.

Main Results:

  • Sobetirome (GC-1) patents indicate a novel therapeutic approach.
  • Key mechanisms include increased hepatic LDL receptor expression.
  • Promotion of reverse cholesterol transport and enhanced biliary sterol secretion were observed.

Conclusions:

  • Thyromimetics, such as sobetirome, show promise for treating dyslipidemia.
  • These agents may effectively lower cholesterol and triglycerides.
  • Sobetirome represents a potential treatment for combined hyperlipidemia and associated cardiovascular risk.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...